Medicine
Thank you virologists! – Nobel Prize spotlights virus-associated cancers
With the 2020 Nobel Prize going to three scientists who led on the discovery of the hepatitis C virus, Adriana Albini acknowledges the valuable contributions that these and other virologists…
Smoke without fire? Should cancer of unknown primary be treated as a separate disease?
Metastases, but no primary tumour – the diagnosis ‘cancer of unknown primary’ still presents great challenges, even in this age of precision oncology. Cancer of unknown primary (CUP) is an…
Does it work for my patient? A pragmatic approach to building evidence on clinical effectiveness
Should patients be at the centre of attention in the development of new cancer drugs? It might seem extraordinary that this question is even asked – what else matters? But…
Are tumour-agnostic approaches the future for oncology?
According to Francesco Pignatti, Head of Oncology at the European Medicines Agency (EMA), the term ‘tumour agnostic’ is a misnomer. The definition of agnostic in ancient greek, he argues, is…
Artificial intelligence for skin cancer diagnosis, from science-fiction to reality
Artificial intelligence (AI) is a hot topic in many sciences, including medicine. A machine capable of making a medical diagnosis in full autonomy is fascinating and highly attractive. “Many years…
Real world data: can we rely on it to shape cancer policies and practice?
In November 2018, the US Food and Drug Administration granted accelerated approval to larotrectinib (Vitrakvi), a drug that targets a neurotrophic receptor tyrosine kinase (NTRK) gene fusion in a range…
CCC-19 and TERAVOLT studies show strength and limits of research on cancer and COVID-19
The virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting2020 hosted a special session on cancer and COVID-19 pandemic. Data from the Thoracic cancERs international…
Evidence-based medicine and precision medicine – irreconcilable or inseparable?
“Medicine cannot be learned quickly, because it is impossible for there to exist any established method in it, as for example when someone who has learned to write in one…
Right drug, wrong patient: here’s how we improve our targeting
When it comes to precision and personalised medicine (PPM), clinical practice in oncology takes pride in developing and administering treatments that selectively target components of tumour cells. But, PPM is…
How to make precision drugs that work better
Six lessons from the development of the first targeted anti-cancer therapy Tamoxifen famously started life as a failed contraceptive, developed by ICI (now Astra Zeneca), but with the fatal flaw…